Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group as of September 30, 2017

Key Data by Segment

Key Data by Segment – Third Quarter 2017

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q3 2016

Q3 2017

 

Q3 2016

Q3 2017

 

Q3 2016

Q3 2017

 

Q3 2016

Q3 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

4,152

4,065

 

1,425

1,320

 

2,057

2,031

 

360

359

Change1

 

+7.3%

−2.1%

 

+0.1%

−7.4%

 

−1.2%

−1.3%

 

+0.8%

−0.3%

Currency-adjusted change1

 

+7.6%

+2.2%

 

+3.6%

−2.9%

 

+2.7%

 

+2.5%

+3.6%

Intersegment sales

 

7

8

 

3

 

7

7

 

6

3

Net sales (total)

 

4,159

4,073

 

1,425

1,323

 

2,064

2,038

 

366

362

EBIT1

 

1,097

1,209

 

194

155

 

135

84

 

81

64

EBIT before special items1

 

1,103

1,206

 

223

173

 

206

205

 

82

72

EBITDA before special items1

 

1,421

1,493

 

328

274

 

318

307

 

89

81

Net cash provided by operating activities

 

998

1,036

 

215

200

 

1,027

841

 

80

68

Depreciation, amortization, impairment losses / loss reversals

 

319

287

 

107

102

 

112

115

 

7

9

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

Q3 2016

Q3 2017

 

Q3 2016

Q3 2017

 

Q3 2016

Q3 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2016 figures restated

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

261

254

 

3

(4)

 

8,258

8,025

Change1

 

+0.4%

−2.7%

 

 

+3.3%

−2.8%

Currency-adjusted change1

 

+0.4%

−5.3%

 

 

+4.5%

+1.3%

Intersegment sales

 

220

583

 

(240)

(604)

 

Net sales (total)

 

481

837

 

(237)

(608)

 

8,258

8,025

EBIT1

 

32

(6)

 

(142)

(118)

 

1,397

1,388

EBIT before special items1

 

45

100

 

(137)

(119)

 

1,522

1,637

EBITDA before special items1

 

94

165

 

(132)

(116)

 

2,118

2,204

Net cash provided by operating activities

 

155

135

 

(106)

(377)

 

2,369

1,903

Depreciation, amortization, impairment losses / loss reversals

 

49

65

 

5

3

 

599

581

Key Data by Segment – 9 Months 2017

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

9M 2016

9M 2017

 

9M 2016

9M 2017

 

9M 2016

9M 2017

 

9M 2016

9M 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

12,145

12,632

 

4,498

4,463

 

7,511

7,314

 

1,194

1,249

Change1

 

+7.3%

+4.0%

 

−1.6%

−0.8%

 

−2.7%

−2.6%

 

+2.0%

+4.6%

Currency-adjusted change1

 

+9.3%

+4.6%

 

+3.3%

−0.8%

 

+0.7%

−3.2%

 

+5.2%

+4.2%

Intersegment sales

 

22

29

 

4

12

 

24

23

 

8

5

Net sales (total)

 

12,167

12,661

 

4,502

4,475

 

7,535

7,337

 

1,202

1,254

EBIT1

 

2,783

3,530

 

627

628

 

1,602

1,171

 

288

297

EBIT before special items1

 

3,031

3,683

 

720

670

 

1,706

1,424

 

290

305

EBITDA before special items1

 

4,034

4,476

 

1,039

980

 

2,070

1,739

 

311

332

Net cash provided by operating activities

 

2,042

2,537

 

653

762

 

1,449

1,332

 

108

134

Depreciation, amortization, impairment losses / loss reversals

 

1,236

939

 

335

320

 

364

352

 

21

27

Number of employees (as of September 30)2

 

39,994

38,110

 

12,909

12,050

 

22,323

20,747

 

3,982

3,554

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

9M 2016

9M 2017

 

9M 2016

9M 2017

 

9M 2016

9M 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2016 figures restated.

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

767

758

 

5

3

 

26,120

26,419

Change1

 

−4.2%

−1.2%

 

 

+2.1%

+1.1%

Currency-adjusted change1

 

−3.6%

−1.4%

 

 

+5.1%

+1.2%

Intersegment sales

 

1,003

1,759

 

(1,061)

(1,828)

 

Net sales (total)

 

1,770

2,517

 

(1,056)

(1,825)

 

26,120

26,419

EBIT1

 

53

14

 

(201)

(362)

 

5,152

5,278

EBIT before special items1

 

91

150

 

(185)

(359)

 

5,653

5,873

EBITDA before special items1

 

235

328

 

(177)

(350)

 

7,512

7,505

Net cash provided by operating activities

 

322

(106)

 

(139)

(304)

 

4,435

4,355

Depreciation, amortization, impairment losses / loss reversals

 

144

178

 

8

9

 

2,108

1,825

Number of employees (as of September 30)2

 

19,550

24,759

 

759

625

 

99,517

99,845